

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/039995 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: PCT/US01/43847

(22) International Filing Date:
6 November 2001 (06.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/714,605 16 November 2000 (16.11.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/714,605 (CON)
Filed on 16 November 2000 (16.11.2000)

(71) Applicant (for all designated States except US): **PHARMACIA & UPJOHN COMPANY** [US/US]; 100 Route 206 North, Peapack, NJ 07977 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PURANDARE, Dinesh** [IN/US]; 6 Macintosh Road, Branchburg, NJ 08876 (US).

(74) Agent: **HILLMAN, Lisa, M., W.**; McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(48) Date of publication of this corrected version:

6 February 2003

(15) Information about Correction:

see PCT Gazette No. 06/2003 of 6 February 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION THERAPY FOR ESTROGEN-DEPENDENT DISORDERS

(57) Abstract: The present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mammals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering to said mammal at least one aromatase inhibitor.



WO 02/039995 A2

COMBINATION THERAPY FOR ESTROGEN-DEPENDENT DISORDERS5 Field of the invention

The present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mammals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering to said mammal at least one aromatase inhibitor.

10

Background of the invention

Various investigators have been studying hormone dependent breast and endometrial cancer. A known form of endocrine therapy in pre-menopausal women is oophorectomy, most commonly performed by surgery or irradiation, two procedures giving irreversible castration. A
15 reversible form oophorectomy of has been achieved by utilizing Luteinizing Hormone Releasing Hormone agonists ("LHRH agonists") which, following inhibition of secretion of Luteinizing Hormone ("LH") by the pituitary gland, decrease serum estrogens to castrated levels (Nicholson et al., Brit. J. Cancer 39, 268-273, 1979).

Several studies show that treatment of pre-menopausal breast cancer patients with
20 LHRH agonists induces responses comparable to those achieved with other forms of castration (Klijn et al., J. Steroid Biochem. 20, 1381, 1984; Manni et al., Endocr. Rev. 7: 89-94; 1986).

U.S. Pat. No. 4,775,660 relates to the treatment of female breast cancer by use of a combination therapy comprising administering an antiandrogen and an antiestrogen to a female after the hormone output of her ovaries has been blocked by chemical or surgical means.

25 U.S. Pat. No. 4,775,661 relates to the treatment of female breast cancer by use of a therapy comprising administering to a female, after the hormone output of her ovaries has been blocked by chemical or surgical means, an antiandrogen and optionally an inhibitor of sex steroid biosynthesis.

U.S. Pat. No. 4,760,053 describes the treatment of selected sex steroid dependent
30 cancers which combines a LHRH agonist and/or an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis.

In U.S. Pat. No. 4,472,382 it is disclosed that prostatic adenocarcinoma, benign prostatic hypertrophy and hormone-dependent mammary tumors may be treated with various LH-RH

agonists and that prostate adenocarcinoma and benign hypertrophy may be treated by use of various LHRH agonists and an antiandrogen.

U.S. Pat. No. 5,550,107 relates to a treatment of female breast and endometrial cancer by use of a therapy comprising administering to a female after the hormone output of the ovaries has been blocked an antiestrogen and at least one compound selected, e.g., from an androgen, a progestin, at least one inhibitor of sex steroid biosynthesis and one inhibitor of prolactin secretion.

Some clinical improvement in pre-menopausal women with breast cancer by use of three LHRH agonists, goserelin, buserelin and leuprolide, is also reported by C.W. Taylor, "Multicenter randomized clinical trial of goserelin vs. surgical ovariectomy in premenopausal patients with receptor positive breast cancer" (J. Clin. Onc. 1998 (16): 994-999), H. A. Harvey et al. "LH-RH analogs in the treatment of human breast cancer", LHRH and its Analogs – A new Class of contraceptive and therapeutic Agents (B. H. Vickery and J. J. Nestor, J., and E. S. E. Hafez, eds) Lancaster, MTP Press, (1984) and the J. G. M. Klijn et al., "Treatment with luteinizing hormone-relating hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer", Lancet 1, 1213-1216 (1982).

Stein R.C. et al. in British Journal of Cancer: 62, 679-683 (1990) describe the clinical and endocrine effects of 4-hydroxyandrostenedione (formestane) alone and in combination with goserelin in premenopausal woman with breast cancer. Celio L. et al. in European Journal of Cancer: S 155 , 691 (17 September 1997) and in Anticancer Research: 19, 2261-268 (1999) describe a study in premenopausal women with breast cancer by treatment with triptorelin and 4-hydroxyandrostenedione. Dowsett M. et al. in Breast Cancer Research and Treatment: 56, 24-35 (1999) describe a combined treatment with vorozole and goserelin of breast cancer in premenopausal women.

Tsuchiya N. et al. in International Journal of Clinical Oncology: (200) 5: 183-187 describe the effects of fadrazole and leuprorelin acetate on cell proliferation in a human breast cancer cell line.

It is an object of the present invention to provide a method for treating estrogen dependent cancers in mammals, in particular sex steroid dependent cancers, said method being not as invasive as surgery.

Detailed description of the invention

The invention provides a method for treating an sex-steroid dependent cancer in a mammal in need of such treatment, including humans, comprising administering

simultaneously, separately or sequentially to said mammal an aromatase inhibitor and a LHRH agonist or antagonist, in amounts and close in time sufficient to achieve a therapeutically useful effect, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuporelin, then the aromatase inhibitor is other than fadrozole.

Preferably such human is a premenopausal woman.

The present invention also provides the use of an aromatase inhibitor in the manufacture of a medicament for treating a sex steroid dependent cancer in a mammal, including humans, undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuporelin, then the aromatase inhibitor is other than fadrozole.

The invention also provides a product containing an aromatase inhibitor and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating sex steroid dependent cancers, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuporelin, then the aromatase inhibitor is other than fadrozole.

The estrogen-dependent cancers that can be treated by the combined therapy method provided by the present invention are cancers known in the art as "sex steroid dependent cancers". Examples of such cancers are testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer and lung cancer.

In one embodiment of the invention, such cancers are prostate cancer, ovarian cancer and breast cancer, in particular breast cancer in a premenopausal woman.

Examples of aromatase inhibitors according to the invention are exemestane, formestane, fadrozole, letrozole, vorozole and anastrozole, preferably exemestane, anastrozole and letrozole, in particular exemestane.

The term "aromatase inhibitor" is meant to comprise both a single aromatase inhibitor or a mixture of two or more, preferably two, aromatase inhibitors as defined above. Preferably the single aromatase inhibitor, or one of the component of the mixture, is exemestane.

Examples of LHRH agonists according to the invention are, e.g., leuporelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001 (5-oxo-L-propyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide) (Peptech), compound AN 207 (6-[N6-[5-[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl) α -L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-1,5-dioxopentyl]-D-lysine]-, (2S-cis)-) (ASTA Medica Inc.), compound AN 238 L-threoninamide, N-[5-[2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl) α -L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethoxy]-1,5-dioxopentyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2,7)-disulfide (ASTA Medica Inc.) and compound SPD 424 (LHRH-hydrogel implant) (Shire Pharmaceuticals Group), or a pharmaceutically acceptable salt thereof.

In one embodiment of the invention, LHRH agonists are triptorelin and goserelin, or a pharmaceutically acceptable salt thereof, in particular triptorelin or a pharmaceutically acceptable salt thereof.

Examples of LHRH antagonists, according to the invention, are e.g. cetorelix, abarelix, ramorelix, teverelix, ganirelix, compounds A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4-chlorophenyl)alanyl-D-(3-pyridyl)alanyl-seryl-(N-methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl-leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide) and A 84861 (Tetrahydrofuran-2-(S)-ylcarbonyl-glycyl-D-(2-naphthyl)alanyl-D-(4-chloro)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N-methyl)tyrosyl-D-[N6-(3-pyridylcarbonyl)]lysyl-L-leucyl-L-(N6-isopropyl)lysyl-L-propyl-D-alanyl-L-alaninamide)(Abbot Labs.), GnRH immunogen (Aphtron Co.), compound T 98475 (Isopropyl 3-(N-benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-(4-isobutylaminophenyl)-4-oxothieno[2,3-b]pyridine-5-carboxylate hydrochloride) (Takeda), and compound MI 1544 (Acetyl-D-tryptophyl-D-cyclopropyl-alanyl-D-tryptophyl-L-seryl-L-tyrosyl-D-lysyl-L-leucyl-L-arginyl-L-propyl-D-alaninamide), or a pharmaceutically acceptable salt thereof. An exemplary LHRH antagonist is abarelix or a pharmaceutically acceptable salt thereof.

The inventors of the present invention have also found that treatment of the above mentioned sex steroid-dependent disorders by combined administration of a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of a LHRH agonist or antagonist, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of sole LHRH agonist or antagonist.

Most importantly, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administration of either therapeutically effective amounts of an aromatase inhibitor or, of the LHRH agonist or antagonist.

As used herein, the term "treating" means in particular "controlling the growth" of the neoplasm, namely slowing, interrupting, arresting, stopping or reversing the neoplasm formation and it does not necessarily indicate a total elimination of the neoplasm.

Therefore, the term "therapeutically useful effect", besides slowing, interrupting, arresting, stopping or reversing, the neoplasm formation, simply also means that the life expectancy of an individual affected with a cancer will be increased, that one or more of the symptoms of the disease will be reduced and/or that quality of life will be enhanced.

Method and Administration

In effecting treatment of a patient in a therapy method according to the invention, the aromatase inhibitor and the LHRH agonist or antagonist can be administered in any form or mode which makes the compounds bioavailable in effective amounts, including oral and parenteral routes.

By the term "administered" or "administering" as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration.

By "parenteral" is meant intravenous, subcutaneous, intradermal or intramuscular administration.

Oral administration includes administering one or both of the constituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.

The actual preferred method and order of administration of the combined preparations of the invention can vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the LHRH agonist or antagonist being utilized, the particular sex steroid-dependent cancer to be treated and the particular patient being treated.

The term "close in time" means that in the combined method of treatment according to the subject invention, the aromatase inhibitor can be administered simultaneously with the LHRH agonist or antagonist or the compounds can be administered sequentially, in either order. However, the compounds are administered in such a way that both inhibition of hormone output

of mammal's testis or ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.

Dosage

5 The dosage ranges for the administration of the combined preparation can vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.

The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associated treatments in a manner which is conventional for any
10 therapy, and can be adjusted in response to changes in conditions and/or in light of other clinical conditions.

An effective amount of an aromatase inhibitor antitumor agent can vary from about 0.5 to about 500 mg per dose 1-2 times a day.

Fadrozole, for example, can be administered orally in a dosage range varying from
15 about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg. Letrozole, for example, can be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg. Formestane, for example, can be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg. Anastrozole, for example, can be administered orally in a dosage
20 range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg. Exemestane for instance can be administered orally in a dosage range varying from about 5 mg daily to about 600 mg daily, in particular from about 10 to about 50, more particularly from about 10 to about 25 mg daily, or parenterally in a dosage ranging from about 50 to about 500 mg per injection.

25 An effective amount of LHRH agonist or antagonist is in general the one commonly used in therapy for such compounds. Goserelin can be administered as goserelin acetate by subcutaneous administration of slow release goserelin at a dosage from about 3 to about 12 mg. Triptorelin can be administered for instance as triptorelin pamaote by intramuscular administration in the form of a depot formulation at a dosage from about 3 to about 20 mg, in
30 such a way that there is an interval of about 1, 2, 3 or 4 months between each administration. In particular triptorelin pamoate can be administered intramuscularly in the form of microparticles as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885, and more specifically as 1-month depot formulation 3.75 mg. For instance, abarelix can be administered as single

intramuscular administration of slow release abarelix 10 to 200 mg every 2 weeks or every month.

The invention provides a method of treating a sex steroid dependent cancer selected from ovarian and breast cancer in a pre-menopausal woman in need of such treatment, comprising administering substantially simultaneously to said woman exemestane and triptorelin or a pharmaceutically acceptable salt thereof, in amounts and close in time sufficient to achieve a therapeutically useful effect.

The term "substantially simultaneous" means that exemestane and triptorelin are administered in such a way that both inhibition of hormone out-put of her ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.

As a further embodiment of the invention it is here also provided the use of exemestane in the manufacture of a medicament for treating a sex steroid dependent cancer selected from ovarian and breast cancer in premenopausal woman, undergoing a substantially simultaneous treatment with triptorelin or a pharmaceutically acceptable salt thereof. In one embodiment of the invention breast cancer is treated.

In one embodiment of the invention, exemestane and triptorelin, in particular as pamoate salt, are administered substantially simultaneously, as herein described, to achieve a therapeutically useful effect.

In particular, triptorelin pamoate can be administered as a sustained release formulation, in such a way that there is an interval from about 1 to 4 months between each administration, e.g. in the form of 1 month depot 3.75 mg formulation, as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885. Exemestane can be administered parenterally at a dosage ranging from about 50 to about 500 mg per injection, or orally at a dosage from about 10 to about 25 mg daily.

As stated above, the invention also provides kits or single packages containing the pharmaceutical compositions useful for the combination treatment of the selected sex steroid-dependent cancers discussed above. The kits or packages can also contain instructions to use the pharmaceutical compositions in accordance with the present invention.

As an example a kit according to the present invention provides an exemestane 25 mg oral or 50-500 mg parenteral composition and a triptorelin 1 month depot formulation 3.75 mg.

A pharmaceutical composition for intramuscular administration containing triptorelin pamoate in the form of a depot formulation can be prepared as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885.

A pharmaceutical composition containing exemestane can be prepared, for example, according to US Pat. No. 4,808,616.

All references cited in this disclosure are incorporated herein by reference.

CLAIMS

1. A method for treating a sex steroid dependent cancer in a mammal in need of such treatment, comprising administering simultaneously, separately or sequentially to said mammal an aromatase inhibitor and a LHRH agonist or antagonist, in amounts sufficient to achieve a therapeutically useful effect and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
2. The method according to claim 1, wherein the sex steroid dependent cancer is selected from the group consisting of testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer and lung cancer.
3. The method according to claim 1, wherein the estrogen-dependent cancer is breast cancer in a premenopausal woman.
4. The method of claim 1, wherein the mammal is a human.
5. The method according to claim 1, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, fadrozole, letrozole, vorozole, anastrozole, and a mixture of two or more of them.
6. The method according to claim 1, wherein the aromatase inhibitor is exemestane.
7. The method according to claim 5, wherein when administered orally, the amount of aromatase inhibitor exemestane is from about 5 to about 600 mg, fadrozole from about 0.5 to about 10 mg, letrozole from about 0.5 to about 10 mg, and anastrozole from about 0.5 to about 10 mg.

8. The method according to claim 5, wherein when administered parenterally, the amount of aromatase inhibitor exemestane is from about 5 to about 500 mg, and formestane is from about 250 to about 500 mg.

5 9. The method according to claim 1, wherein the LHRH agonist is selected from the group consisting of leuporelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001 (5-oxo-L-propyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide), compound AN 207 (6-
10 [N6-[5-[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl) α -L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-1,5-dioxopentyl]-D-lysine]-,(2S-cis)-), compound AN 238 (L-threoninamide, N-[5-[2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl) α -L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethoxy]-1,5-dioxopentyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-
15 cysteinyl-, cyclic (2 7)-disulfide), compound SPD 424 (LHRH-hydrogel implant), and a pharmaceutically acceptable salt thereof.

10. The method according to claim 1, wherein the LHRH agonist is selected from triptorelin, goserelin, and a pharmaceutically acceptable salt thereof.

11. The method according to claim 1, wherein the LHRH agonist is triptorelin or a pharmaceutically acceptable salt thereof.

12. The method according to claim 1, wherein the LHRH agonist is triptorelin pamoate.

13. The method according to claim 1, wherein the LHRH agonist triptorelin pamoate is in the form of a depot formulation, at a dosage from about 3 to about 20 mg.

14. The method according to claim 13, wherein the LHRH agonist triptorelin pamoate is in the form of a 1 month depot formulation 3.75 mg.

15. The method according to claim 1, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, abarelix, ramorelix, teverelix, ganirelix, compound A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4-chlorophenyl)alanyl-D-(3-pyridyl)alanyl-seryl-(N-

methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl-leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide), compound A 84861 (Tetrahydrofuran-2-(S)-ylcarbonyl-glycyl-D-(2-naphthyl)alanyl-D-(4-chloro)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N-methyl)tyrosyl-D-[N6-(3-pyridylcarbonyl)]lysyl-L-leucyl-L-(N6-isopropyl)lysyl-L-propyl-D-alanyl-L-
5 GnRH immunogen, compound T 98475 (Isopropyl 3-(N-benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-(4-isobutyrylamino)phenyl)-4-oxothieno[2,3-b]pyridine-5-carboxylate hydrochloride), compound MI 1544 (Acetyl-D-tryptophyl-D-cyclopropylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-D-lysyl-L-leucyl-L-arginyl-L-propyl-D-alaninamide), and a pharmaceutically acceptable salt thereof.

10

16. A method of treating a sex steroid dependent cancer selected from ovarian and breast cancer in a pre-menopausal woman in need of such treatment, comprising administering to said woman exemestane and triptorelin or a pharmaceutically acceptable salt thereof, in amounts sufficient to achieve a therapeutically useful effect.

15

17. The method according to claim 16, wherein both inhibition of hormone out-put of the women's ovaries and inhibition/inactivation of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.

20

18. The method according to claim 16, wherein the estrogen dependent cancer is breast cancer.

19. The method according to claim 16, wherein triptorelin is in the form of triptorelin pamoate salt.

25

20. The method according to claim 16, wherein triptorelin pamoate is in the form of a depot formulation.

21. The method according to claim 16, wherein triptorelin pamoate is in the form of 1 month depot formulation 3.75 mg.

30

22. The method according to claim 16, wherein about 5 to 600 mg/day of exemestane is administered orally.

12

23. The method according to claim 16, wherein about 10 to 500 mg/day of exemestane is administered orally.

24. The method according to claim 16, wherein about 25 mg/day of exemestane is administered orally.

25. The method according to claim 16, wherein about 50 to 500 mg/day of exemestane is administered parenterally.

26. Use of an aromatase inhibitor in the manufacture of a medicament for treating a sex steroid dependent cancer in a mammal undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.

27. Use according to claim 26, wherein the mammal is a human.

28. Use according to claim 26, wherein the aromatase inhibitor is exemestane, the LHRH agonist is triptorelin and the sex steroid dependent cancers are ovarian and breast cancers.

29. Product containing an aromatase inhibitor and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating sex-dependent cancers, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/039995 A3

(51) International Patent Classification⁷: **A61K 38/09**,
A61P 35/00 // (A61K 38/09, 31:565)

(21) International Application Number: PCT/US01/43847

(22) International Filing Date:
6 November 2001 (06.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/714,605 16 November 2000 (16.11.2000) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:

US 09/714,605 (CON)
Filed on 16 November 2000 (16.11.2000)

(71) Applicant (for all designated States except US): **PHAR-
MACIA & UPJOHN COMPANY** [US/US]; 100 Route
206 North, Peapack, NJ 07977 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PURANDARE, Di-
nesh** [IN/US]; 6 Macintosh Road, Branchburg, NJ 08876
(US).

(74) Agent: **HILLMAN, Lisa, M., W.**; McDonnell Boehnen
Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive,
Chicago, IL 60606 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:
— with international search report

(88) Date of publication of the international search report:
1 May 2003

(15) Information about Correction:
Previous Correction:
see PCT Gazette No. 06/2003 of 6 February 2003, Sec-
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATION THERAPY FOR ESTROGEN-DEPENDENT DISORDERS

(57) Abstract: The present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mam-
mals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering
to said mammal at least one aromatase inhibitor.



WO 02/039995 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/43847

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K38/09 A61P35/00 //(A61K38/09,31:565)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCOTT LESLEY J ET AL: "Exemestane." DRUGS, vol. 58, no. 4, October 1999 (1999-10), pages 675-680, XP001104951 ISSN: 0012-6667 page 676, column 2 page 681, column 2	1-29
Y	LONNING P E ET AL: "ACTIVITY OF EXEMESTANE IN METASTATIC BREAST CANCER AFTER FAILURE OF NONSTEROIDAL AROMATASE INHIBITORS: A PHASE II TRIAL" JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 18, no. 11, June 2000 (2000-06), pages 2234-2244, XP001034132 page 2234, column 2 --- -/-	1-29

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 September 2002

Date of mailing of the international search report

16. 10. 02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/43847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BAJETTA E ET AL: "The Minimal Effective Exemestane Dose for Endocrine Activity in Advanced Breast Cancer" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 4, April 1997 (1997-04), pages 587-591, XP004282560 ISSN: 0959-8049 page 587, column 2 ---	1-29
Y	EXEMESTANE STUDY GROUP THURLIMANN B ET AL: "Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Aminoglutethimide: a Phase II Multicentre Multinational Study" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 11, October 1997 (1997-10), pages 1767-1773, XP004284524 ISSN: 0959-8049 page 1767, column 1-2 page 1768, column 1-2 ---	1-29
Y	BRODIE A M H ET AL: "Aromatase inhibitors and their application in breast cancer treatment*" STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 65, no. 4, April 2000 (2000-04), pages 171-179, XP004202992 ISSN: 0039-128X abstract; figure 2 page 173-174 ---	1-29
Y	LONNING PER E: "Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer." BREAST CANCER RESEARCH AND TREATMENT, vol. 49, no. SUPPL. 1, 1998, pages S45-S52, XP001105373 ISSN: 0167-6806 abstract page S45, column 2 See clinical effects figure 1 --- -/--	1-29

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/43847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CELIO LUIGI ET AL: "Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study." ANTICANCER RESEARCH, vol. 19, no. 3B, May 1999 (1999-05), pages 2261-2268, XP000986987 ISSN: 0250-7005 cited in the application See Results tables 2,3</p>	1-14, 16-29
Y	<p>TSUCHIYA NAOKO ET AL: "Effects of fadrozole and leuprorelin acetate on aromatase activity and cell proliferation in a human breast cancer cell line (SK-BR-3)." INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol. 5, no. 3, June 2000 (2000-06), pages 183-187, XP001069659 ISSN: 1341-9625 cited in the application Discussion figures 1-4</p>	1-14, 16-29
Y	<p>DOWSETT MITCHELL ET AL: "Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer." BREAST CANCER RESEARCH AND TREATMENT, vol. 56, no. 1, July 1999 (1999-07), pages 25-34, XP001069646 ISSN: 0167-6806 cited in the application Results, discussion figure 2</p>	1-14, 16-29
Y	<p>STEIN R C ET AL: "THE CLINICAL AND ENDOCRINE EFFECTS OF 4 HYDROXYANDROSTENEDIONE ALONE AND IN COMBINATION WITH GOSERELIN IN PREMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER" BRITISH JOURNAL OF CANCER, vol. 62, no. 4, 1990, pages 679-683, XP001069642 ISSN: 0007-0920 cited in the application Discussion table 1</p>	1-14, 16-29
	<p>---</p> <p>--- -/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/43847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NORMAN P: "CETRORELIX ASTA MEDICA AG" CURRENT OPINION IN ONCOLOGIC, ENDOCRINE AND METABOLIC INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON,, GB, vol. 2, no. 2, 2000, pages 227-248, XP000982761 ISSN: 1464-8466 See clinical development	1-8,15, 26,27,29
Y	MANETTA A ET AL: "INHIBITION OF GROWTH OF HUMAN OVARIAN CANCER IN NUDE MICE BY LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONIST CETRORELIX (SB-75)" FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, US, vol. 63, no. 2, 1 February 1995 (1995-02-01), pages 282-287, XP002088625 ISSN: 0015-0282 See "Results"	1-8,15, 26,27,29
Y	REISSMANN T ET AL: "The LHRH antagonist cetorelix: a review." HUMAN REPRODUCTION UPDATE. ENGLAND 2000 JUL-AUG, vol. 6, no. 4, July 2000 (2000-07), pages 322-331, XP001097713 ISSN: 1355-4786 page 328 -page 329	1-8,15, 26,27,29
Y	DOEHN C ET AL: "Technology evaluation: Abarelix, Praecis pharmaceuticals." CURRENT OPINION IN MOLECULAR THERAPEUTICS. ENGLAND OCT 2000, vol. 2, no. 5, October 2000 (2000-10), pages 579-585, XP001105426 ISSN: 1464-8431 See clinical development	1-8,15, 26,27,29
Y	MONTAGNANI M M ET AL: "EFFECTS OF LHRH AGONISTS ON THE GROWTH OF HUMAN PROSTATIC TUMOR CELLS: IN VITRO AND IN VIVO STUDIES" ARCHIVIO ITALIANO DI UROLOGIA, LICINIO COPPELLI, BOLOGNA, IT, vol. 69, no. 4, September 1997 (1997-09), pages 257-263, XP002927944 ISSN: 0365-351X abstract Conclusions	1,2, 4-14,26, 27,29

	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/43847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MILLAR J L: "Triptorelin approved for prostate cancer treatment." AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY: AJHP: OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS. UNITED STATES 1 AUG 2000, vol. 57, no. 15, 1 August 2000 (2000-08-01), page 1386 XP001105066 ISSN: 1079-2082 the whole document	1,2, 4-14,26, 27,29
Y	KELLOFF G J ET AL: "Aromatase inhibitors as potential cancer chemopreventives." CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION: A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY. UNITED STATES JAN 1998, vol. 7, no. 1, January 1998 (1998-01), pages 65-78, XP001105199 ISSN: 1055-9965 the whole document	1,2, 4-14,26, 27,29
Y	KARP J E ET AL: "Prostate cancer prevention: investigational approaches and opportunities." CANCER RESEARCH. UNITED STATES 15 DEC 1996, vol. 56, no. 24, 15 December 1996 (1996-12-15), pages 5547-5556, XP002113055 ISSN: 0008-5472 table 2	1,2, 4-14,26, 27,29
Y	WISEMAN L R ET AL: "Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer." DRUGS. NEW ZEALAND JAN 1993, vol. 45, no. 1, January 1993 (1993-01), pages 66-84, XP001105072 ISSN: 0012-6667 the whole document	1,2, 5-14,26, 27,29

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/43847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BENALI NAOUAL ET AL: "Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 9180-9185, XP002165128 ISSN: 0027-8424 AN-238 (LHRH agonist) for treatment of pancreatic carcinoma, ---	1,2,4-9, 26,27,29
Y	DATABASE CANCERLIT AN= 91676029 'Online! COMARU-SCHALLY A M ET AL: "LHRH AGONISTS AS ADJUNCTS TO SOMATOSTATIN ANALOGS IN THE TREATMENT OF PANCREATIC CANCER." retrieved from STN Database accession no. 91676029 XP002213988 abstract & GNRH ANALOGUES CANCER HUMAN REPRODUCTION, (1990) 3 203-10., Veterans Administration Medical Center, 1601 Perdido St., New Orleans, LA 70146. abstract ---	1,2,4-9, 26,27,29
A	BRODIE A M H ET AL: "AROMATASE INHIBITORS IN ADVANCED BREAST CANCER: MECHANISM OF ACTION AND CLINICAL IMPLICATIONS" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 66, no. 1/2, July 1998 (1998-07), pages 1-10, XP000986681 ISSN: 0960-0760 the whole document ---	26-29
P,Y	WO 00 69467 A (SALLE ENRICO DI ;ZACCHEO TIZIANA (IT); PHARMACIA & UPJOHN SPA (IT)) 23 November 2000 (2000-11-23) claims; example 1; table 1 ---	26-29
P,Y	WO 01 49294 A (MASSIMINI GIORGIO ;PHARMACIA & UPJOHN SPA (IT); PISCITELLI GABRIEL) 12 July 2001 (2001-07-12) claims 1,5 -----	1,2, 4-14,26, 27,29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/43847

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

Partially, to the extent they are related to the first four inventions
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor exemestane in combination with an LHRH agonist, (in particular triptorelin or goserelin) and the use of that product in relation to the treatment of ovarian, breast, uterin, fallopian tube, celomic epithelial and germ cell ovarian cancers.

2. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor exemestane in combination with an LHRH antagonist, and the use of that product in relation to the treatment of ovarian, breast, uterin, fallopian tube, celomic epithelial and germ cell ovarian cancers.

3. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor exemestane in combination with an LHRH agonist or antagonist, (in particular triptorelin or gonerelein) and the use of that product in relation to the treatment of testicular and prostate cancers.

4. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor exemestane in combination with an LHRH agonist or antagonist, (in particular triptorelin or goserelin) and the use of that product in relation to the treatment of pancreatic, and lung cancers.

5. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor formestane in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of ovarian, breast, uterin, fallopian tube, celomic epithelial and germ cell ovarian cancers.

6. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor formestane in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of testicular and prostate cancers.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor formestane in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of pancreatic, and lung cancers.

8. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor fadrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of ovarian, breast, uterin, fallopian tube, celomic epithelial and germ cell ovarian cancers.

9. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor fadrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of testicular and prostate cancers.

10. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor fadrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of pancreatic, and lung cancers.

11. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor letrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of ovarian, breast, uterin, fallopian tube, celomic epithelial and germ cell ovarian cancers.

12. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor letrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of testicular and prostate cancers.

13. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor letrozole in combination with an LHRH agonist or antagonist, and the use

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

of that product in relation to the treatment of pancreatic, and lung cancers.

14. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor vorozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of ovarian, breast, uterin, fallopian tube, celomic epithelial and germ cell ovarian cancers.

15. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor vorozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of testicular and prostate cancers.

16. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor vorozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of pancreatic, and lung cancers.

17. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor anastrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of ovarian, breast, uterin, fallopian tube, celomic epithelial and germ cell ovarian cancers.

18. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor anastrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of testicular and prostate cancers.

19. Claims: 26-29 (partial)

A product comprising the aromatase inhibitor anastrozole in combination with an LHRH agonist or antagonist, and the use of that product in relation to the treatment of pancreatic, and lung cancers.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/43847

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0069467	A	23-11-2000	AU	3820700 A		05-12-2000
			WO	0069467 A1		23-11-2000
			EP	1178831 A1		13-02-2002
WO 0149294	A	12-07-2001	AU	3157001 A		16-07-2001
			WO	0149294 A1		12-07-2001